Reducing the relative value of cigarettes: Considerations for nicotine and non-nicotine factors

Cassidy M. White; Dorothy K. Hatsukami; Eric C. Donny

doi:10.1016/j.neuropharm.2020.108200

Reducing the relative value of cigarettes: Considerations for nicotine and non-nicotine factors

Cassidy M. White, Dorothy K. Hatsukami, Eric C. Donny

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Despite notable progress in recent decades, cigarette smoke persists as a leading cause of premature death and preventable disease. To weaken the link between nicotine reinforcement and the toxicity associated with combusted tobacco, the United States Food and Drug Administration is considering a product standard targeting cigarette nicotine content. In this review, we summarize research assessing the potential impacts of reducing nicotine in cigarettes. Evidence to date suggests cigarette smoking, toxicant exposure and dependence would decline following substantial reductions in nicotine content. However, reduced nicotine content may not eliminate smoking entirely. Regulatory efforts that shape the nicotine and tobacco marketplace should consider that non-nicotine reinforcing factors and decision-making biases can contribute to the value of smoking. The impact of reducing nicotine in cigarettes will likely depend on the alternative nicotine products available to current smokers. This article is part of the special issue on 'Contemporary Advances in Nicotine Neuropharmacology'.

Original language	English (US)
Article number	108200
Journal	Neuropharmacology
Volume	175
DOIs	https://doi.org/10.1016/j.neuropharm.2020.108200
State	Published - Sep 15 2020

Bibliographical note

Funding Information:
Effort on this project was supported by the National Institute on Drug Abuse and the Food and Drug Administration Center for Tobacco Products ( U54-DA031659 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Food and Drug Administration. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA.

Funding Information:
Effort on this project was supported by the National Institute on Drug Abuse and the Food and Drug Administration Center for Tobacco Products (U54-DA031659). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Food and Drug Administration. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA.

Publisher Copyright:
© 2020 Elsevier Ltd

Keywords

Low nicotine cigarettes
Nicotine dependence
Nicotine reduction
Tobacco regulatory science

PubMed: MeSH publication types

Review
Research Support, U.S. Gov't, P.H.S.
Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.neuropharm.2020.108200

Find It

Find It at U of M Libraries

Cite this

@article{ff15c3eff01e4f168d214687bde92976,

title = "Reducing the relative value of cigarettes: Considerations for nicotine and non-nicotine factors",

abstract = "Despite notable progress in recent decades, cigarette smoke persists as a leading cause of premature death and preventable disease. To weaken the link between nicotine reinforcement and the toxicity associated with combusted tobacco, the United States Food and Drug Administration is considering a product standard targeting cigarette nicotine content. In this review, we summarize research assessing the potential impacts of reducing nicotine in cigarettes. Evidence to date suggests cigarette smoking, toxicant exposure and dependence would decline following substantial reductions in nicotine content. However, reduced nicotine content may not eliminate smoking entirely. Regulatory efforts that shape the nicotine and tobacco marketplace should consider that non-nicotine reinforcing factors and decision-making biases can contribute to the value of smoking. The impact of reducing nicotine in cigarettes will likely depend on the alternative nicotine products available to current smokers. This article is part of the special issue on 'Contemporary Advances in Nicotine Neuropharmacology'.",

keywords = "Low nicotine cigarettes, Nicotine dependence, Nicotine reduction, Tobacco regulatory science",

author = "White, {Cassidy M.} and Hatsukami, {Dorothy K.} and Donny, {Eric C.}",

note = "Funding Information: Effort on this project was supported by the National Institute on Drug Abuse and the Food and Drug Administration Center for Tobacco Products ( U54-DA031659 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Food and Drug Administration. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA. Funding Information: Effort on this project was supported by the National Institute on Drug Abuse and the Food and Drug Administration Center for Tobacco Products (U54-DA031659). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Food and Drug Administration. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = sep,

day = "15",

doi = "10.1016/j.neuropharm.2020.108200",

language = "English (US)",

volume = "175",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Reducing the relative value of cigarettes

T2 - Considerations for nicotine and non-nicotine factors

AU - White, Cassidy M.

AU - Hatsukami, Dorothy K.

AU - Donny, Eric C.

N1 - Funding Information: Effort on this project was supported by the National Institute on Drug Abuse and the Food and Drug Administration Center for Tobacco Products ( U54-DA031659 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Food and Drug Administration. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA. Funding Information: Effort on this project was supported by the National Institute on Drug Abuse and the Food and Drug Administration Center for Tobacco Products (U54-DA031659). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Food and Drug Administration. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA. Publisher Copyright: © 2020 Elsevier Ltd

PY - 2020/9/15

Y1 - 2020/9/15

N2 - Despite notable progress in recent decades, cigarette smoke persists as a leading cause of premature death and preventable disease. To weaken the link between nicotine reinforcement and the toxicity associated with combusted tobacco, the United States Food and Drug Administration is considering a product standard targeting cigarette nicotine content. In this review, we summarize research assessing the potential impacts of reducing nicotine in cigarettes. Evidence to date suggests cigarette smoking, toxicant exposure and dependence would decline following substantial reductions in nicotine content. However, reduced nicotine content may not eliminate smoking entirely. Regulatory efforts that shape the nicotine and tobacco marketplace should consider that non-nicotine reinforcing factors and decision-making biases can contribute to the value of smoking. The impact of reducing nicotine in cigarettes will likely depend on the alternative nicotine products available to current smokers. This article is part of the special issue on 'Contemporary Advances in Nicotine Neuropharmacology'.

AB - Despite notable progress in recent decades, cigarette smoke persists as a leading cause of premature death and preventable disease. To weaken the link between nicotine reinforcement and the toxicity associated with combusted tobacco, the United States Food and Drug Administration is considering a product standard targeting cigarette nicotine content. In this review, we summarize research assessing the potential impacts of reducing nicotine in cigarettes. Evidence to date suggests cigarette smoking, toxicant exposure and dependence would decline following substantial reductions in nicotine content. However, reduced nicotine content may not eliminate smoking entirely. Regulatory efforts that shape the nicotine and tobacco marketplace should consider that non-nicotine reinforcing factors and decision-making biases can contribute to the value of smoking. The impact of reducing nicotine in cigarettes will likely depend on the alternative nicotine products available to current smokers. This article is part of the special issue on 'Contemporary Advances in Nicotine Neuropharmacology'.

KW - Low nicotine cigarettes

KW - Nicotine dependence

KW - Nicotine reduction

KW - Tobacco regulatory science

UR - http://www.scopus.com/inward/record.url?scp=85086573253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086573253&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2020.108200

DO - 10.1016/j.neuropharm.2020.108200

M3 - Review article

C2 - 32535010

AN - SCOPUS:85086573253

SN - 0028-3908

VL - 175

JO - Neuropharmacology

JF - Neuropharmacology

M1 - 108200

ER -

Reducing the relative value of cigarettes: Considerations for nicotine and non-nicotine factors

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this